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Abstract
Background: Researchers have recently advocated for the 2-minute walk (2MW) as an alternative for the 6-minute
walk (6MW) to assess long distance ambulation in persons with multiple sclerosis (MS). This recommendation has
not been based on physiological considerations such as the rate of oxygen consumption (V·O2) over the 6MW
range.
Objective: This study examined the pattern of change in V·O2 over the range of the 6MW in a large sample of
persons with MS who varied as a function of disability status.
Method: Ninety-five persons with clinically-definite MS underwent a neurological examination for generating an
Expanded Disability Status Scale (EDSS) score, and then completion of the 6MW protocol while wearing a portable
metabolic unit and an accelerometer.
Results: There was a time main effect on V·O2 during the 6MW (p = .0001) such that V·O2 increased significantly
every 30 seconds over the first 3 minutes of the 6MW, and then remained stable over the second 3 minutes of the
6MW. This occurred despite no change in cadence across the 6MW (p = .84).
Conclusions: The pattern of change in V·O2 indicates that there are different metabolic systems providing energy
for ambulation during the 6MW in MS subjects and steady state aerobic metabolism is reached during the last 3
minutes of the 6MW. By extension, the first 3 minutes would represent a test of mixed aerobic and anaerobic
work, whereas the second 3 minutes would represent a test of aerobic work during walking.
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Background
Walking performance has been identified as a key out-
come variable in clinical trials and practice involving
persons with multiple sclerosis (MS) [1]. This is based
on its association with disease progression [2] and value
as an important personal function [3] with profound
implications for independence, quality of life, and activ-
ities of daily living for many patients [4].
Accordingly, there has been an increased interest in
applying walking performance tests as clinical outcomes
in MS. The 6-minute walk (6MW) represents a walking
performance test [5] that has received attention as a
promising clinical outcome in this population [6-8]. The
6MW appears to provide unique, and perhaps more
sensitive, information about the walking performance of
persons with MS compared with other tests such as the
short distance timed 25-foot walk or the ambulatory
steps of the 500-meter walk of the Expanded Disability
Status Scale (EDSS) [2].
Some researchers have advocated for a 2-minute walk
(2MW) rather than 6MW [9,10] for MS clinical trials.
The 2MW is reported to be as valid a measure of walk-
ing performance as the 6MW, but it presumably has
less strain and demand on the participant and test
administrator and therefore appears more feasible. The
comparable validity is based on a strong correlation
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similar pattern of correlations with external criteria
[9,10]. Importantly, correlations alone might not suffi-
ciently address differences in what the 2MW and 6MW
are capturing or the clinical meaningfulness of the
observed changes.
Another perspective on identifying the appropriate
duration of walking performance tests might involve
consideration of physiological variables such as the
rate of oxygen consumption (V·O2). For example, there
is abundant evidence in healthy controls that V·O2
increases in a curvilinear manner over the initial 2-3
minutes of submaximal exercise until reaching a pla-
teau or “steady-state” that is maintained over the
remainder of submaximal exercise [11,12]. This curvi-
linear increase in V·O2 reflects the lag between ener-
getic supply and demand such that there is greater
energy supplied by anaerobic processes than aerobic
oxidation during the initiation of submaximal exercise
[11,12]. If the period of time before reaching steady-
state V·O2 extends beyond 2-minutes of submaximal
exercise in persons with MS, this would suggest that
the 2MW and 6MW represent physiologically different
measures of ambulatory performance whose equiva-
lence for MS patients can n o tb ea s s u m e d .T h e2 M W
conceptually would represent a test of aerobic and
non-aerobic walking performance, whereas the 6MW
would represent a test of aerobic or endurance walking
performance.
To date, studies have measured V·O2 during the 6MW
in persons with MS [13,14], but those studies have typi-
cally assumed steady-state V·O2 over the last 3 minutes
of submaximal exercise and have not documented the
actual pattern of change in V·O2 o v e rt h ee n t i r e6 M W .
Only one study has examined the pattern of change in
V·O2 over the entire 6MW [15], but this was in a small
sample of persons with MS (N =1 1 )a n dt h es t u d yd i d
not account for disability status. Disability status has
been associated with 6MW performance [6,7] and oxy-
gen cost of walking [14] in MS, and might further
impact the magnitude and pattern of change in V O2
over the course of the 6MW.
This study examined the pattern of change in V·O2
o v e rt h ec o u r s eo ft h e6 M Wi nal a r g es a m p l eo fp e r -
sons with MS. We further examined the possibility that
the pattern of change in V·O2 over the course of the
6MW might vary as a function of mild, moderate, and
severe disability status. Such an examination is impor-
tant for identifying a physiologic basis for decisions
regarding the actual duration of walking performance
tests in persons with MS.
Methods
Sample
The sample was recruited through referrals from three
locally residing neurologists and consisted of 95 persons
with clinically-definite MS. The two inclusion criteria
were (a) capacity for independent ambulation or ambu-
lation with an assistive device and (b) willingness to
complete testing. Persons who had a relapse or under-
went administration of steroids in the past 30 days were
excluded from participation.
Procedure
The procedure was approved by a local Institutional
Review Board and participants provided written
informed consent. The data were collected during a sin-
gle session in a clinical setting. The participants initially
provided demographic information and then underwent
a neurological examination for generating an EDSS
score [16]. This was followed by attachment of a porta-
ble metabolic unit and an accelerometer, and then com-
pletion of the 6MW protocol. All participants received
$20 remuneration.
Measures
Six-minute walk
The 6MW was performed in a rectangular, carpeted
corridor with hallways that exceed 50 m in length and
that were clear of obstructions and foot traffic. We pro-
vided standardized instructions and emphasized walking
as far and as fast as possible for 6 minutes [6]. One
researcher followed along side of the participant for
safety, while another researcher followed 3 feet behind
the participant and recorded the distance travelled (ft)
using a measuring wheel (Stanley MW50, New Briton,
CT) [7]. If the patient reported a history of falls during
ambulation, we placed a gait belt around the person’s
waist and followed very closely in the event of a slip,
trip, or stumble that might cause a fall during the 6MW.
Oxygen consumption
V·O2 was measured breath-by-breath during the 6MW
using a commercially available portable metabolic unit
(K4b
2 Cosmed, Italy). The O2 and CO2 analyzers of the
portable metabolic unit along with the battery were con-
nected to a harness that was worn on the trunk like a
backpack; this portable unit is small (170 × 55 × 100
mm) and light weight (475 g). The flow meter was
attached to a mouthpiece that was worn on the partici-
pant’sf a c ec o v e r i n gb o t ht h en o s ea n dm o u t h .T h eO 2
and CO2 analyzers of the portable metabolic unit were
calibrated using verified concentrations of gases, and the
flow-meter was calibrated using a 3-L syringe (Hans
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second averages over the 6MW.
Cadence
Steps per minute were measured by an ActiGraph
model GT3X accelerometer (Health One Technology,
Fort Walton Beach, FL) as a method of monitoring
cadence during the 6MW. The accelerometer was worn
on an elastic belt around the waist and above the non-
dominant hip. The sampling epoch was 1 second.
Cadence was calculated as total steps per minute over
the 6MW and this device is accurate under controlled
conditions in persons with MS [17].
Data analysis
All data analyses were performed in PASW statistics
18.0. We provided descriptive statistics as mean ± stan-
dard deviation (SD) in text and mean ± standard error
of the mean (SEM) in Figures. We examined differences
in 6MW distance between groups using one-way
ANOVA. We examined differences in cadence and V·O2
over the 6MW using two-way group by time ANOVA.
Post-hoc analyses were performed with an automatic
Bonferronni correction of alpha. The effect sizes for the
ANOVAs were expressed as eta-squared (h
2)w i t h
values of .01, .06, and .14 indicating small, moderate,
and large effects, respectively [18]. We expressed effect
sizes for differences in mean as Cohen’s d with values of
0.2, 0.5, and 0.8 indicating small, moderate, and large
effects, respectively [18].
Results
Sample characteristics
The mean age of the sample was 52.8 ± 11.1 yr and the
gender distribution was predominantly female (76
women/19 men). The sample primarily had a relapsing-
remitting clinical course (n = 78, 82.1% of cases) with
the other cases of MS representing secondary progres-
sive (n = 8, 8.4% of cases) and primary progressive (n =
5, 5.3% of cases) clinical courses; there was missing
information regarding disease course for 4 (4.2% of
cases) participants. The mean disease duration of the
sample was 11.9 ± 10.0 yr. Of the 95 persons, 80 or
84.2% were on a disease-modifying therapy and 62 or
65.3% were on a symptomatic therapy. Based on a neu-
rological examination, the median EDSS score was 4.5
with a range between 2.0 and 6.5. This range of EDSS
scores permitted formation of three groups consisting of
mild (n = 29, EDDS = 2-3.5), moderate (n = 29, EDDS
= 4.0-5.5), and severe (n = 37, EDDS = 6.0-6.5) disability
consistent with disability benchmarks in epidemiological
studies of MS [19].
There was a strong group main effect of disability sta-
tus on 6MW distance, F(2,92) = 60.25, p = .0001, h
2 =
.58. Those with mild disability walked significantly
further than those with moderate (d = 1.30) and severe
(d = 2.66) disability, and those with moderate disability
walked significantly further than those with severe dis-
ability (d = 1.44). The mean 6MW distances for those
with mild, moderate, and severe disability were 1723 ±
252 ft, 1389 ± 264 ft, and 979 ± 300 ft, respectively.
Interestingly, the coefficients of variation (100 × SD/M)
for mild, moderate, and severe disability were 15%, 19%,
and 31%, respectively.
There was a strong group main effect on cadence
(steps/minute) during the 6MW, F(2,91) = 22.82, p =
.0001, h
2 = .33. Those with mild disability took signifi-
cantly more steps per minute during the 6MW than
those with moderate (d = 0.66) and severe (d = 1.64)
disability, and those with moderate disability took signif-
icantly more steps per minute during the 6MW than
those with severe disability (d = 0.99). This is illustrated
in Figure 1. Cadence did not differ over the 6MW by
time, F(5,455) = 0.42, p =. 8 4 ,h
2 = .01, or group and
time, F(10,455) = 1.08, p = .37, h
2 = .02.
T h e r ew a sav e r ys t r o n gt i m em a i ne f f e c to nV · O 2
during the 6MW, F(11,1012) = 357.58, p = .0001, h
2 =
.80, as well as a moderate group main effect, F(2,92) =
4.41, p = .015, h
2 = .09, and a moderate group by time
interaction, F(22,1012) = 4.66, p = .0001, h
2 = .09. Over-
all, V·O2 increased significantly every 30 seconds over
the first 3 minutes of the 6MW, and then remained
stable over the second 3 minutes of the 6MW; this is
illustrated in Figure 2. The overall pattern of change in
V·O2 over the 6MW was not changed in additional ana-
lyses that controlled for the presence/absence of dis-
ease-modifying or symptomatic therapy. The rate of
increase in V·O2 was steeper in those with mild disabil-
ity than those with moderate and severe disability based
on the interaction, and those with mild disability had a
higher rate of V·O2 than those with moderate and severe
disability based on the group main effect.
Discussion
Researchers have recently advocated for a 2MW rather
than a 6MW as a walking performance test in persons
with MS, and this is based on a strong correlation
between distances and similar correlations with external
criteria [9,10]. This evidence alone is not sufficient for
selecting a single test duration given the likely different
physiological and metabolic demands of the 2MW and
6MW and the heterogeneous disability of individual MS
patients. Accordingly, for this study we adopted a phy-
siological perspective for understanding the appropriate
duration of a walking performance test in MS, and we
p r o v i d ed a t ao nt h ep a t t e r no fc h a n g ei nV · O 2 over the
6MW at various degrees of disability using the EDSS as
gold standard. V·O2 changed in a curvilinear pattern
during the first 3 minutes of the 6MW, and then
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changes in V·O2 over the remainder of the 6MW. Such
a pattern of change in V·O2 occurred despite similar
pacing over the entire 6MW based on cadence mea-
sured by an accelerometer. This is explained by the lag
in aerobic oxidation during the initiation of steady-state,
submaximal exercise [11,12]. Overall, the pattern of
change in V·O2 suggests that there are different meta-
bolic systems providing energy for ambulation during
phases of the 6MW. Both aerobic and anaerobic systems
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Figure 1 Cadence (steps/minute) over the six-minute walk test for persons with mild (n = 29), moderate (n = 29), and severe (n = 37)
disability scores.
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Figure 2 Oxygen consumption (milliliters/minute) over the six-minute walk test for persons with mild (n = 29), moderate (n = 29), and
severe (n = 37) disability scores.
Motl et al. BMC Neurology 2012, 12:6
http://www.biomedcentral.com/1471-2377/12/6
Page 4 of 7are providing energy for walking in the first part of the
6MW, whereas aerobic metabolism is the primary
energy system used for walking during the second part
of the 6MW. This observation might be further exam-
ined by administering tests of anaerobic and aerobic
power and examining the association with 2MW and
6MW performance in persons with MS. Anaerobic
power could be measured using a Wingate Test (i.e.,
pedal a manually braked bicycle ergometer for 30 sec-
onds with an all out pace), whereas aerobic power could
be measured using a maximal, incremental exercise test
(i.e., pedal an electronically braked ergometer over 10-
12 minute period with increasing resistance until voli-
tional termination). Such tests can be administered in
persons with MS and would provide further information
on the physiological and metabolic systems underlying
2MW and 6MW performance. This would be important
for identifying the possibility that these tests measure
different features of walking and therefore have different
interpretations or applications as clinical outcome
variables.
We compared our data on the pattern of change in
V·O2 over the 6MW with previous research involving
persons with MS [15]. That previous research included
a small sample of persons with MS (n = 11) and
reported that V·O2 increased over the first 3 minutes of
the 6MW and then reached steady-state over the
remainder of the test. This pattern of change was con-
sistent with that observed during submaximal exercise
in non-diseased, healthy adults [11,12], but the level of
increase in V·O2 during the 6MW is higher in controls
than persons with MS [15]; this is expected based on
the difference in walking speed, but has not been exam-
ined across levels of disability status in MS versus con-
trols. We confirmed that V·O2 increases over the first 3
minutes of the 6MW and then reaches “steady state,”
but in a nearly 10 times larger sample of persons with
MS. We further reported on the novel result that the
pattern of change over the first 3 minutes was generally
consistent across mild, moderate, and severe disability
status, although the slope was steeper and the absolute
level of V·O2 was higher in those with mild disability
compared with moderate and severe disability. This is
caused, in part, by the difference in walking speed and
its associated effect on V·O2.I np a r t i c u l a r ,i fw e
expressed V·O2 relative to walking speed (i.e., oxygen
cost of walking), there would be a difference between
the moderate and severe disability groups given similar
energy expenditure, but different walking speed. Never-
theless, there appears to be consistent evidence for a
curvilinear pattern of change in V·O2 over the first 3
minutes of the 6MW in MS, and this has implications
for identifying the primary source of energy for walking
during the 2MW and 6MW. The pattern of change in
V·O2 would suggest that the 2MW represents a test of
both aerobic and anaerobic aspects of walking perfor-
mance, whereas the 6MW represents a test of primarily
aerobic or endurance aspects of walking performance in
MS. Conceptually, 2MW performance might be asso-
ciated with everyday tasks that require brief, but intense
bouts of ambulation (e.g., stair climbing or crossing the
street), whereas 6MW performance might be associated
with everyday tasks that require sustained, submaximal
bouts of ambulation (e.g., grocery shopping).
We compared our data on the 6MW with those of
previous research [6] for further understanding the vera-
city of this performance test for differentiating disability
status in MS. That previous research [6] observed a
reduction in walking distance (mean ± standard devia-
tion in ft) across three levels of disability status, namely
mild (1958 ± 155 ft; EDSS = 0-2.5; n = 15), moderate
(1636 ± 332 ft; EDSS = 3-4; n = 19), and severe (1254 ±
259 ft; EDSS = 4.5-6.5; n = 6) disability. We observed a
similar reduction in walking distance across the three
levels of disability status of mild (1723 ft; EDSS = 2-3.5;
n = 29), moderate (1389 ft; EDSS = 4-5.5; n = 29), and
severe (979 ft; EDSS = 6.0-6.5; n = 37) disability. Inter-
esting, the coefficient of variability was larger for per-
sons with moderate and severe disability than mild
disability in the present study and previous research [6].
We further note that all participants walked for the
entire 6-minute period, and we had no falls or other
adverse events. This too is similar with the observations
of previous research [6]. Overall, we replicated the capa-
city of the 6MW for differentiating disability status, par-
ticularly in the severe group that had a small sample
size in previous research [6], and recommend that the
6MW continue to be considered as a performance
assessment of walking endurance in MS as it is in other
neurological conditions such as Parkinson’sd i s e a s e
[20,21].
We measured cadence during the 6MW using an
accelerometer as an initial method of examining spatio-
temporal parameters of pacing; this has not been under-
t a k e ni np r e v i o u sr e s e a r c h .Interestingly, we observed
that cadence (i.e., steps per minute) did not change over
the 6MW for any of the groups who differed in disabil-
ity status, but it did differ significantly among the three
groups. Those with mild disability had a greater cadence
during the 6MW than those with moderate and severe
disability, and those with moderate disability had a
greater cadence during the 6MW than those with severe
disability. This indicates that the spatiotemporal para-
meters of pacing do not change over the 6MW in per-
sons with MS (i.e., persons select and maintain a stable
cadence over the entire 6MW) perhaps to optimize
energy expenditure, and future researchers might con-
sider other temporal and spatial parameters of gait such
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been an observation of possible differences in minute-
by-minute walking speeds during the 6MW across dis-
a b i l i t ys t a t u s[ 6 ] .W en o t et h a tt h e r em i g h tb ed i f f e r e n t
neural systems controlling step rate and length in MS,
and perhaps this is important for monitoring in clinical
trials of MS. Of note, the sample in the present study
has a different disability composition than that of the
previous publication examining changes in performance
pattern during the 6MW [6]. This issue could be further
explored through application of devices such as the
Intelligent Device for Energy Expenditure and Physical
Activity or IDEEA
® or GAITRite™ electronic walkway
and might further our understanding of gait parameters
that are associated with long distance walking perfor-
mance and identify targets of rehabilitation for improv-
ing this valued function.
We did not administer an independent 2MW in this
study and have no information on V·O2 over the actual
2MW test. Nevertheless, we suspect that V·O2 would
actually be similar during the 2MW compared with the
first 2 minutes of the 6MW. This is based on the similar
distance walked during the 2MW and first 2 minutes of
the 6MW in persons with MS [10]. By extension, walk-
ing speed would be comparable between the 2MW and
first 2 minutes of the 6MW and result in a similar
metabolic demand. This observation is important as it
minimizes the concern that our results regarding change
in V·O2 over the initial part of the 6MW are not applic-
able for the 2MW. However, even if the change in V·O2
was not applicable it would not undermine our argu-
ment that there are different metabolic processes under-
lying the 2MW and 6MW, as one would expect a
steeper slope of the V·O2 response if the intensity was
actually greater when performing the 2MW test. Never-
theless, such assumptions should be confirmed in subse-
quent research along with the recommendation of
administering tests of anaerobic and aerobic power in
MS.
There are notable strengths of the current study
including the standardized administration of the 6MW
protocol, measurement of V·O2 and cadence over the
6MW, and relatively large sample of persons with MS
and subsamples with a proportionate range of disability
status. The limitations include (a) lack of a control
group for further comparing V·O2, cadence, and dis-
tance over the 6MW, (b) lack of measurement of V·O2
and cadence over the 2MW, (c) the cross-sectional
design and lack of information on the comparative sen-
sitivity and responsiveness for capturing change in
2MW and 6MW performance over time and in the con-
text of an intervention trial, (d) lack of external criteria
for validating the 2MW and 6MW against anaerobic
and aerobic power, and (e) lack of control for fatigue
levels and exact types of symptomatic therapies that
might impact ambulation, V·O2, and cadence.
Conclusion
We provide new data on V·O2 and cadence over the
6MW across disability status, and the data on V·O2 over
the 6MW, in particular, has implications for decisions
regarding the domain of long distance walking to be
captured in future applications of the 2MW and 6MW
tests in MS and perhaps other neurological conditions.
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